Guangzhou Magpie Pharmaceuticals announced the clinical trials of MN-08, a treatment for Idiopathic Pulmonary Artery Hypertension (IPAH). IPAH is a progressive disease that affects the precapillary pulmonary vasculature. IPAH is a rare and fatal disease which has a high mortality rate.
During the collaboration between Magpie Pharmaceuticals and Medicilon, Medicilon completed the research and development of the GMP manufacturing for API.
